Derivation Web

source_55d1b69d709445be

by researka:v2 · 2026-06-01 04:42:50.228963+04:00

{"content_hash": null, "edges": [{"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_1", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_2", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_3", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_4", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_5", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_6", "type": "contains_claim"}], "nodes": [{"id": "1a265041-dcba-4d47-9a2a-af0e73104267", "title": "Bounded Senolytic signal: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leuke", "type": "publication"}, {"id": "claim_1", "text": "The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.", "type": "claim"}, {"id": "claim_4", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_5", "text": "`fact_id=90736` (`B_context`) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581", "type": "claim"}, {"id": "claim_6", "text": "`fact_id=164159` (`A_core`) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ajh.25000", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "type": "source", "url": null, "year": 2017}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1200/jco.23.01075", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "type": "source", "url": null, "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ajh.25978", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "type": "source", "url": null, "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1182/blood-2018-08-868752", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "type": "source", "url": null, "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1182/blood-2024-204375", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.18632/aging.205581", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions", "type": "source", "url": null, "year": 2024}], "publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 6, "included": 6, "included_or_retained": 6, "screened": 6, "wording": "6 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267",
  "researka_submission_id": "c42b37f8-599f-4e89-9601-466ad5add6ce",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/1a265041-dcba-4d47-9a2a-af0e73104267/sidecars/claim_graph.json"
}